Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 15, 2024
Daily News
November 15, 2024
- Alexion Japan Wants to Extend 2-Digit Growth, Ride on Reform Boon: Next Chief
November 15, 2024
- JPMA Appreciates Growing Calls for Abolition of Off-Year Revisions: Exec
November 15, 2024
- LDP Broadly OKs Draft Economic Package, Adds Text on FY2025 Revision
November 15, 2024
- EMA Backs Leqembi after Re-Examination, but for Limited Use
November 15, 2024
- Stella Pharma Ties Up with TLS for Borofalan in US, Europe
November 15, 2024
- MSD Files PAH Treatment Sotatercept in Japan
November 15, 2024
- MHLW Orders Label Revisions for Epadel, Lotriga, and More
November 15, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…